摘要
目的 :探讨大黄虫丸对大鼠肝星状细胞表达转化生长因子β1(TGF β1)的影响。方法 :用CCl4复合因素致大鼠肝纤维化模型 ,同时分别给予 3种剂量大黄虫丸治疗 ,免疫组化方法观察TGF β1、α 平滑肌肌动蛋白 (α SMA)的合成表达及纤维化程度分级。结果 :经给予大黄虫丸干预治疗常规剂量组大鼠TGF β1、α SMA表达与模型组比较差异无显著性 (P >0 0 5 ) ,但双倍剂量组和三倍剂量组TGF β1、α SMA在汇管区及不连续纤维间隔的表达明显减弱 (P <0 0 5 ,P <0 0 1)。结论 :大黄虫丸较大剂量能抑制肝星状细胞增殖和分泌TGF β1,减少胶原生成 ,从而减弱肝星状细胞的自分泌放大效应 ,这可能是大黄虫丸抗肝纤维化作用的主要机制之一。
Objective: To explore the effect of Dahuang Zhechong Pill (DHZCP) on transforming growth factor-β 1 (TGF-β 1) in rats hepatic stellate cells. Methods: Liver fibrosis model rats were induced by CCl 4 compound factor, and treated with DHZCP in three different dosages (ordinary, double and triple) separately. TGF-β 1 and α-smooth muscle actin (α-SMA) synthesis expression, and grades of fibrosis were observed. Results: TGF-β 1 and α-SMA expression in the group treated with ordinary dose of DHZCP was insignificantly different from those in the control group (P>0.05), but the expression attenuated significantly after treatment with double or triple dose of DHZCP in the portal area and discontinuous fibrous septum (P<0.05, P<0.01). Conclusion: DHZCP of larger dosage could inhibit the hepatic stellate cells proliferation and secretion of TGF-β 1, and reduce the genesis of collagen, so as to weaken the auto-secretion amplifying response of the cells, which might be one of the chief mechanisms of DHZCP in antagonizing liver fibrosis.
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
2003年第10期763-766,共4页
Chinese Journal of Integrated Traditional and Western Medicine
基金
广东省珠海市重点科技攻关项目 (No.0 1 2 6)
